Oncomethylome to Test Methylation Biomarkers on Abbott's Samples | GenomeWeb
NEW YORK (GenomeWeb News) – The drug developer Abbott has tapped Oncomethylome to profile tumors for its cancer drug research efforts, Oncomethylome said today.
 
Oncomethylome will use its high-throughput DNA methylation platform to test its biomarkers on biological samples provided by Abbot, the company said.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.